MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 562307 | Name: Sultopride HCl
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sultopride is a selective D2 and D3 receptor antagonist. Sultopride was 4-6 times as potent as sulpiride in stimulating prolactin secretion. Sultopride neutralized the dopamine-mediated inhibition of prolactin secretion from the anterior pituitary in vitro. sultopride, like sulpiride, stimulates prolactin secretion by blocking the dopamine receptor in the pituitary.

Chemical Structure

Sultopride HCl
Sultopride HCl
CAS#23694-17-9 (HCl)

Theoretical Analysis

MedKoo Cat#: 562307

Name: Sultopride HCl

CAS#: 23694-17-9 (HCl)

Chemical Formula: C17H27ClN2O4S

Exact Mass: 0.0000

Molecular Weight: 390.92

Elemental Analysis: C, 52.23; H, 6.96; Cl, 9.07; N, 7.17; O, 16.37; S, 8.20

Price and Availability

Size Price Availability Quantity
50mg USD 550.00 2 Weeks
100mg USD 950.00 2 Weeks
200mg USD 1,450.00 2 Weeks
1g USD 4,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
23694-17-9 (HCl) 53583-79-2 (free base)
Synonym
Sultopride Hydrochloride; Sultopride HCl; Barnotil; LIN 1418; LIN-1418; LIN1418; LIN 1418;
IUPAC/Chemical Name
N-((1-Ethylpyrrolidin-2-yl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide hydrochloride
InChi Key
IGOWMQPOGQYFFM-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H26N2O4S.ClH/c1-4-19-10-6-7-13(19)12-18-17(20)15-11-14(24(21,22)5-2)8-9-16(15)23-3;/h8-9,11,13H,4-7,10,12H2,1-3H3,(H,18,20);1H
SMILES Code
O=C(NCC1N(CC)CCC1)C2=CC(S(=O)(CC)=O)=CC=C2OC.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 390.92 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Barber S, Olotu U, Corsi M, Cipriani A. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database Syst Rev. 2017 Mar 23;3:CD006324. doi: 10.1002/14651858.CD006324.pub3. Review. PubMed PMID: 28333365. 2: Sampford JR, Sampson S, Li BG, Zhao S, Xia J, Furtado VA. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2016 Jul 2;7:CD010832. doi: 10.1002/14651858.CD010832.pub2. Review. PubMed PMID: 27370402. 3: Ozaki M. [Characteristics and Functional Roles of Opioids Originally Present in Vivo]. Yakugaku Zasshi. 2016;136(4):591-605. doi: 10.1248/yakushi.15-00265. Review. Japanese. PubMed PMID: 27040344. 4: Silvestre FJ, Silvestre-Rangil J, López-Jornet P. Burning mouth syndrome: a review and update. Rev Neurol. 2015 May 16;60(10):457-63. Review. English, Spanish. PubMed PMID: 25952601. 5: Leucht S, Winter-van Rossum I, Heres S, Arango C, Fleischhacker WW, Glenthøj B, Leboyer M, Leweke FM, Lewis S, McGuire P, Meyer-Lindenberg A, Rujescu D, Kapur S, Kahn RS, Sommer IE. The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. Schizophr Bull. 2015 May;41(3):549-58. doi: 10.1093/schbul/sbv019. Epub 2015 Mar 18. Review. PubMed PMID: 25786408; PubMed Central PMCID: PMC4393704. 6: Andersen CU, Høimark L, Dabrowski K, Hansen KB, Sædder E. [Sparse evidence of antipsychotic drugs for the treatment of delirium]. Ugeskr Laeger. 2014 Apr 14;176(16). pii: V11130658. Review. Danish. PubMed PMID: 25351397. 7: McLoughlin BC, Pushpa-Rajah JA, Gillies D, Rathbone J, Variend H, Kalakouti E, Kyprianou K. Cannabis and schizophrenia. Cochrane Database Syst Rev. 2014 Oct 14;(10):CD004837. doi: 10.1002/14651858.CD004837.pub3. Review. PubMed PMID: 25314586. 8: Andersen CU, Høimark L, Dabrowski K, Hansen KB, Sædder E. [Sparse evidence of antipsychotic drugs for the treatment of delirium]. Ugeskr Laeger. 2014 Sep 29;176(40). pii: V11130658. Review. Danish. PubMed PMID: 25294505. 9: Rico-Villademoros F, Calandre EP, Slim M. Current status of atypical antipsychotics for the treatment of fibromyalgia. Drugs Today (Barc). 2014 Jun;50(6):435-44. doi: 10.1358/dot.2014.50.6.2127023. Review. PubMed PMID: 24983591. 10: Pasquini M, Berardelli I, Calabrò F, Roselli V, Hefner S, Biondi M. Is amisulpride safe when prescribed to breast and prostate cancer patients? Med Hypotheses. 2013 Dec;81(6):1146-50. doi: 10.1016/j.mehy.2013.08.031. Epub 2013 Sep 18. Review. PubMed PMID: 24134827. 11: Wang HR, Woo YS, Bahk WM. Atypical antipsychotics in the treatment of delirium. Psychiatry Clin Neurosci. 2013 Jul;67(5):323-31. doi: 10.1111/pcn.12066. Review. PubMed PMID: 23859663. 12: Osser DN, Roudsari MJ, Manschreck T. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia. Harv Rev Psychiatry. 2013 Jan-Feb;21(1):18-40. doi: 10.1097/HRP.0b013e31827fd915. Review. PubMed PMID: 23656760. 13: Voicu V, Medvedovici A, Ranetti AE, Rădulescu FŞ. Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences. Expert Opin Drug Metab Toxicol. 2013 Aug;9(8):955-68. doi: 10.1517/17425255.2013.791283. Epub 2013 Apr 21. Review. PubMed PMID: 23600946. 14: Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, Christiaens T. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2013 Mar 28;(3):CD007726. doi: 10.1002/14651858.CD007726.pub2. Review. PubMed PMID: 23543555. 15: Needham E, Hamelijnck J. Temporal lobe epilepsy masquerading as psychosis--a case report and literature review. Neurocase. 2012;18(5):400-4. doi: 10.1080/13554794.2011.627338. Epub 2011 Nov 29. Review. PubMed PMID: 22124330. 16: Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD006626. doi: 10.1002/14651858.CD006626.pub2. Review. PubMed PMID: 21249678; PubMed Central PMCID: PMC4167865. 17: Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD008121. doi: 10.1002/14651858.CD008121.pub2. Review. PubMed PMID: 21154393. 18: Chen J, Gao K, Kemp DE. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry. 2011 Jan;24(1):10-7. doi: 10.1097/YCO.0b013e3283413505. Review. PubMed PMID: 21088586. 19: Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010 Nov;123(2-3):225-33. doi: 10.1016/j.schres.2010.07.012. Epub 2010 Aug 7. Review. PubMed PMID: 20692814; PubMed Central PMCID: PMC2957510. 20: Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006654. doi: 10.1002/14651858.CD006654.pub2. Review. PubMed PMID: 20238348; PubMed Central PMCID: PMC4169107.